Vitamin D deficiency in HIV infection: An underestimated and undertreated epidemic

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 9, 2013, Pages 1218-1232

  Pinzone, M R ^a   Di Rosa, M ^a   Malaguarnera, M ^a   Madeddu, G ^b   Foca E ^c   Ceccarelli, G ^d   D'Ettorre, G ^d   Vullo, V ^d   Fisichella, R ^a   Cacopardo, B ^a   Nunnari, G ^a,e  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF SASSARI   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Bone disease; HAART; HIV; Hypovitaminosis D; Vitamin D

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ANTIRETROVIRUS AGENT; COLECALCIFEROL; DARUNAVIR; EFAVIRENZ; PARATHYROID HORMONE; PROTEINASE INHIBITOR; RILPIVIRINE; ZIDOVUDINE;

ARTICLE; BONE DENSITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CHRONIC KIDNEY DISEASE; COGNITION; DIETARY INTAKE; DISEASE ASSOCIATION; EPIDEMIC; FRAGILITY FRACTURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; INSULIN RESISTANCE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL STATUS; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; SCREENING; SKIN PIGMENTATION; SUN EXPOSURE; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BONE DISEASES; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY; VITAMINS;

EID: 84878598674     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (152)

1. PALELLA FJ, BAKER RK, MOORMAN AC, CHMIEL JS, WOOD KC, BROOKS JT, HOLMBERG SD, HIV OUTPATIENT STUDY INVESTIGATORS. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27-34.
2. DEEKS SG, PHILLIPS AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 2009; 338: a3172.
3. BHAVAN KP, KAMPALATH VN, OVERTON ET. The aging of the HIV epidemic. Curr HIV/AIDS Rep 2008; 5: 150-158.
4. MARTELLOTTA F, BERRETTA M, VACCHER E, SCHIOPPA O, ZANET E, TIRELLI U. AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res 2009; 7: 634-638.
5. BERRETTA M, CINELLI R, MARTELLOTTA F, SPINA M, VACCHER E, TIRELLI U. Therapeutic approaches to AIDS-related malignancies.Oncogene 2003; 22: 6646-6659.
6. NUNNARI G, BERRETTA M, PINZONE MR, DI ROSA M, CAPPELLANI A, BERRETTA S, TIRELLI U, MALAGUARNERA M, SCHNELL JM, CACOPARDO B. Hepatocellular carcinoma in HIV positive patients. Eur Rev Med Pharmacol Sci 2012; 16: 1257-1270.
7. PINZONE MR, FIORICA F, DI ROSA M, MALAGUARNERA G, MALAGUARNERA L, CACOPARDO B, ZANGHÌ G, NUNNARI G. Non-AIDS-defining cancers among HIV-infected people. Eur Rev Med Pharmacol Sci 2012; 16: 1377-1388.
8. DORNADULA G, NUNNARI G, VANELLA M, ROMAN J, BABINCHAK T, DESIMONE J, STERN J, BRAFFMAN M, ZHANG H, POMERANTZ RJ. Human immunodeficiency virus type 1-infected persons with residual disease and virus reservoirs on suppressive highly active antiretroviral therapy can be stratified into relevant virologic and immunologic subgroups. J Infect Dis 2001; 183: 1682-1687.
9. NUNNARI G, OTERO M, DORNADULA G, VANELLA M, ZHANG H, FRANK I, POMERANTZ RJ. Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections. AIDS 2002; 16: 39-45.
10. NUNNARI G, LETO D, SULLIVAN J, XU Y, MEHLMAN KE, KULKOSKY J, POMERANTZ RJ. Seminal reservoirs during an HIV type 1 eradication trial. AIDS Res Hum Retroviruses 2005; 21: 768-775.
11. NUNNARI G, SULLIVAN J, XU Y, NYIRJESY P, KULKOSKY J, CAVERT W, FRANK I, POMERANTZ RJ. HIV type 1 cervicovaginal reservoirs in the era of HAART. AIDS Res Hum Retroviruses 2005; 21: 714-718.
12. NUNNARI G, ARGYRIS E, FANG J, MEHLMAN KE, POMERANTZ RJ, DANIEL R. Inhibition of HIV-1 replication by caffeine and caffeine-related methylxanthines. Virology 2005; 335: 177-184.
13. SMITH JA, NUNNARI G, PREUSS M, POMERANTZ RJ, DANIEL R. Pentoxifylline suppresses transduction by HIV-1- based vectors. Intervirology 2007; 50: 377-386.
14. PINZONE MR, DI ROSA M, CACOPARDO B, NUNNARI G. HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol 2012; 2012: 515962.
15. BERRETTA M, DI BENEDETTO F, DAL MASO L, CACOPARDO B, NASTI G, FACCHINI G, BEARZ A, SPINA M, GARLASSI E, DE RE V, FIORICA F, LLESHI A, TIRELLI U. Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients. Anticancer Drugs 2013; 24: 212-218.
16. ZANET E, BERRETTA M, DI BENEDETTO F, TALAMINI R, BALLARIN R, NUNNARI G, BERRETTA S, RIDOLFO A, LLESHI A, ZANGHÌ A, CAPPELLANI A, TIRELLI U. Pancreatic cancer in HIV-positive patients: a clinical casecontrol study. Pancreas 2012; 41: 1331-1335.
17. ZANET E, BERRETTA M, MARTELLOTTA F, CACOPARDO B, FISICHELLA R, TAVIO M, BERRETTA S, TIRELLI U. Anal cancer: focus on HIV-positive patients In the HAART Era. Curr HIV Res 2011; 9: 70-81.
18. BEARZ A, VACCHER E, TALAMINI R, BERRETTA M, TIRELLI U. Comment on 'Lung cancer in the Swiss HIV Cohort Study: role of smoking, immunodeficiency and pulmonary infection'. Br J Cancer 2012; 106: 1899-1900.
19. BERRETTA M, GARLASSI E, CACOPARDO B, CAPPELLANI A, GUARALDI G, COCCHI S, DE PAOLI P, LLESHI A, IZZI I, TORRESIN A, DI GANGI P, PIETRANGELO A, FERRARI M, BEARZ A, BERRETTA S, NASTI G, DI BENEDETTO F, BALESTRERI L, TIRELLI U, VENTURA P. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Oncologist 2011; 16: 1258-1269.
20. DI BENEDETTO F, DE RUVO N, BERRETTA M, MASETTI M, MONTALTI R, DI SANDRO S, BALLARIN R, CODELUPPI M, GUARALDI G, GERUNDA GE. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008; 34: 422-427.
21. BERRETTA M, TIRELLI U. Colorectal cancer screening in HIV-infected patients 50 years of age and older: missed opportunities for prevention. Am J Gastroenterol 2006; 101: 907.
22. BERRETTA M, LLESHI A, CAPPELLANI A, BEARZ A, SPINA M, TALAMINI R, CACOPARDO B, NUNNARI G, MONTESARCHIO V, IZZI I, LANZAFAME M, NASTI G, BASILE F, BERRETTA S, FISICHELLA R, SCHIANTARELLI C, GARLASSI E, RIDOLFO A, GUELLA L, TIRELLI U. Oxaliplatin based chemotherapy and concomitant highly active antiretroviral therapy in the treatment of 24 patients with colorectal cancer and HIV infection. Curr HIV Res 2010; 8: 218-222.
23. NUNNARI G, SMITH JA, DANIEL R. HIV-1 Tat and AIDSassociated cancer: targeting the cellular anti-cancer barrier. J Exp Clin Cancer Res 2008; 27: 3.
24. BERRETTA M, CAPPELLANI A, DI BENEDETTO F, LLESHI A, TALAMINI R, CANZONIERI V, ZANET E, BEARZ A, NASTI G, LACCHIN T, BERRETTA S, FISICHELLA R, BALESTRERI L, TORRESIN A, IZZI I, ORTOLANI P, TIRELLI U. Clinical presentation and outcome of colorectal cancer in hivpositive patients: a clinical case-control study. Onkologie 2009; 32: 319-324.
25. SPINA M, BERRETTA M, TIRELLI U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003; 17: 843-858.
26. OTERO M, NUNNARI G, LETO D, SULLIVAN J, WANG FX, FRANK I, XU Y, PATEL C, DORNADULA G, KULKOSKY J, POMERANTZ RJ. Peripheral blood Dendritic cells are not a major reservoir for HIV type 1 in infected individuals on virally suppressive HAART. AIDS Res Hum Retroviruses 2003; 19: 1097-1103.
27. PINZONE MR, CACOPARDO B, CONDORELLI F, DI ROSA M, NUNNARI G. Sirtuin-1 and HIV-1: an overview. Curr Drug Targets 2013 Apr 3 [Epub ahead of print].
28. NUNNARI G, XU Y, ACHEAMPONG EA, FANG J, DANIEL R, ZHANG C, ZHANG H, MUKHTAR M, POMERANTZ RJ. Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection. J Neurovirol 2005; 11: 319-328.
29. NUNNARI G, POMERANTZ RJ. IL-7 as a potential therapy for HIV-1-infected individuals. Expert Opin Biol Ther 2005; 5: 1421-1426.
30. KULKOSKY J, BOUHAMDAN M, GEIST A, NUNNARI G, PHINNEY DG, POMERANTZ RJ. Pathogenesis of HIV-1 infection within bone marrow cells. Leuk Lymphoma 2000; 37: 497-515.
31. POMERANTZ RJ, NUNNARI G. HIV and GB virus C- can two viruses be better than one? N Engl J Med 2004; 350: 963-965.
32. PINZONE MR, CELESIA BM, DI ROSA M, CACOPARDO B, NUNNARI G. Microbial translocation in chronic liver diseases. Int J Microbiol 2012; 2012: 694629.
33. APPAY V, SAUCE D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214: 231-241.
34. NIXON DE, LANDAY AL. Biomarkers of immune dysfunction in HIV.Curr Opin HIV AIDS 2010; 5: 498-503.
35. STONE B, DOCKRELL D, BOWMAN C, MCCLOSKEY E. HIV and bone disease. Arch Biochem Biophys 2010; 503: 66-77.
36. KNOBEL H, GUELAR A, VALLECILLO G, NOGUES X, DIEZ A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15: 807-808.
37. CAZANAVE C, DUPON M, LAVIGNOLLE-AURILLAC V, BARTHE N, LAWSON-AYAYI S, MEHSEN N, MERCIÉ P, MORLAT P, THIÉBAUT R, DABIS F, GROUPE D'EPIDÉMIOLOGIE CLINIQUE DU SIDA EN AQUITAINE. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008; 22: 395-402.
38. TEBAS P, POWDERLY WG, CLAXTON S, MARIN D, TANTISIRIWAT W, TEITELBAUM SL, YARASHESKI KE. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14: F63-67.
39. BROWN TT, QAQISH RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20: 2165-2174.
40. TRIANT VA, BROWN TT, LEE H, GRINSPOON SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93: 3499-3504.
41. CALMY A, FUX CA, NORRIS R, VALLIER N, DELHUMEAU C, SAMARAS K, HESSE K, HIRSCHEL B, COOPER DA, CARR A. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 2009; 200: 1746-1754.
42. OVERTON ET, MONDY K, BUSH T. Factors Associated with Low Bone Mineral Density in a Large Cohort of HIV-infected US Adults: Baseline Results from the SUN Study. Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections 2007. Los Angeles, CA: Abstract 836.
43. ARNSTEN JH, FREEMAN R, HOWARD AA, FLORISMOORE M, LO Y, KLEIN RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21: 617-623.
44. STEIN EM, YIN MT, MCMAHON DJ, SHU A, ZHANG CA, FERRIS DC, COLON I, DOBKIN JF, HAMMER SM, SHANE E. Vitamin D deficiency in HIV-infected postmenopausal Hispanic and African-American women. Osteoporos Int 2010; 22: 477-487.
45. YIN MT, LU D, CREMERS S, TIEN PC, COHEN MH, SHI Q, SHANE E, GOLUB ET, ANASTOS K. Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr 2010; 53: 202-208.
46. SEMINARI E, CASTAGNA A, SOLDARINI A, GALLI L, FUSETTI G, DORIGATTI F, HASSON H, DANISE A, GUFFANTI M, LAZZARIN A, RUBINACCI A. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Med 2005; 6: 145-150.
47. GARCIA APARICIO AM, FERNÁNDEZ SM, GONZÁLEZ J, ARRIBAS JR, PEÑA JM, VÁZQUEZ JJ, MARTÍNEZ ME, COYA J, MARTÍN MOLA E. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006; 25: 537-539.
48. TEICHMANN J, STEPHAN E, LANGE U, DISCHER T, FRIESE G, LOHMEYER J, STRACKE H, BRETZEL RG. Osteopenia in HIV infected women prior to highly active antiretroviral therapy. J Infect 2003; 46: 221-227.
49. BIKLE D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab 2009; 94: 26-34.
50. DI ROSA M, MALAGUARNERA G, DE GREGORIO C, PALUMBO M, NUNNARI G, MALAGUARNERA L. Immuno- modulatory effects of vitamin D3 in human monocyte and macrophages. Cell Immunol 2012; 280: 36-43.
51. DI ROSA M, MALAGUARNERA L, NICOLOSI A, SANFILIPPO C, MAZZARINO C, PAVONE P, BERRETTA M, COSENTINO S, CACOPARDO B, PINZONE MR, NUNNARI G. Vitamin D3: an ever green molecule. Front Biosci (Schol Ed) 2013; 5: 247-260.
52. NUNNARI G, COCO C, PINZONE MR, PAVONE P, BERRETTA M, DI ROSA M, SCHNELL M, CALABRESE G, CACOPARDO B. The role of micronutrients in the diet of HIV- 1-infected individuals. Front Biosci (Elite Ed) 2012; 4: 2442-2456.
53. CACOPARDO B, CAMMA C, PETTA S, PINZONE MR, CAPPELLANI A, ZANGHI A, NICOLOSI A, NUNNARI G. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. Front Biosci (Elite Ed). 2012; 4: 1276-1286.
54. MOZOLOWSKI W. Jedrzej Sniadecki (1768-1838) on the cure of rickets. Nature 1939; 143: 121.
55. HOLICK MF. Vitamin D Deficiency. N Engl J Med 2007; 357: 266-281.
56. PROSSER DE, JONES G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004; 29: 664-673.
57. STOFFELS K, OVERBERGH L, BOUILLON R, MATHIEU C. Immune regulation of 1alpha-hydroxylase in murine peritoneal macrophages: unravelling the IFN-gamma pathway. J Steroid Biochem Mol Biol 2007; 103: 567-571.
58. OMDAHL JL, MORRIS HA, MAY BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr 2002; 22: 139-166.
59. HYPPÖNEN E, LÄÄRÄ E, REUNANEN A, JÄRVELIN MR, VIRTANEN SM. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001; 358: 1500-1503.
60. WANG TJ, PENCINA MJ, BOOTH SL, JACQUES PF, INGELSSON E, LANIER K, BENJAMIN EJ, D'AGOSTINO RB, WOLF M, VASAN RS. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-511.
61. HINES SL, JORN HK, THOMPSON KM, LARSON JM. Breast cancer survivors and vitamin D: a review. Nutrition 2010; 26: 255-262.
62. GORHAM ED, GARLAND CF, GARLAND FC, GRANT WB, MOHR SB, LIPKIN M, NEWMARK HL, GIOVANNUCCI E, WEI M, HOLICK MF. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005; 97: 179-194.
63. LIU PT, STENGER S, TANG DH, MODLIN RL. Cutting edge: vitamin D-mediated human antimicrobial activity against Mycobacterium tuberculosis is dependent on the induction of cathelicidin. J Immunol 2007; 179: 2060-2063.
64. KRUTZIK SR, HEWISON M, LIU PT, ROBLES JA, ROBLES JA, STENGER S, ADAMS JS, MODLIN RL. IL-15 links TLR2/1-induced macrophage differentiation to the vitamin D-dependent antimicrobial pathway. J Immunol 2008; 181: 7115-7120.
65. NNOAHAM KE, CLARKE A. Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int J Epidemiol 2008; 37: 113-119.
66. GINDE AA, MANSBACH JM, CAMARGO JR CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169: 384-390.
67. ADAMS JS, HEWISON M. Unexpected actions of vitamin D: new perspectives on the regulation of innate and adaptive immunity. Nat Clin Pract Endocrinol Metab 2008; 4: 80-90.
68. PROVVEDINI DM, TSOUKAS CD, DEFTOS LJ, MANOLAGAS SC. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science 1983; 221: 1181-1183.
69. CAMPBELL GR, SPECTOR SA. Hormonally active vitamin D3 (1,25-Dihydroxycholecalciferol) triggers autophagy in human macrophages that inhibits HIV-1 infection. J Biol Chem 2011; 286: 18890-18902.
70. ADAMS JS, HEWISON M. Update in Vitamin D. J Clin Endocrinol Metab 2010; 95: 471-478.
71. ARABI A, EL RASSI R, EL-HAJJ FULEIHAN G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nat Rev Endocrinol 2010; 6: 550-561.
72. GINDE AA, LIU MC, CAMAARGO CA. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169: 626-632.
73. YETLEY EA. Assessing the vitamin D status of the US population. Am J Clin Nutr 2008; 88: 558S- 564S.
74. DAO CN, PATEL P, OVERTON ET, RHAME F, PALS SL, JOHNSON C, BUSH T, BROOKS JT, AND THE STUDY TO UNDERSTAND THE NATURAL HISTORY OF HIV AND AIDS IN THE ERA OF EFFECTIVE THERAPY (SUN) INVESTIGATORS. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011; 52: 396-405.
75. VIARD JP, SOUBERBIELLE JC, KIRK O, REEKIE J, KNYSZ B, LOSSO M, GATELL J, PEDERSEN C, BOGNER JR, LUNDGREN JD, MOCROFT A, FOR THE EUROSIDA STUDY GROUP. Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011; 25: 1305-1315.
76. WELZ T, CHILDS K, IBRAHIM F, POULTON M, TAYLOR CB, MONIZ CF, POST FA. Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS 2010; 24: 1923-1928.
77. ALLAVENA C, DELPIERRE C, CUZIN L, REY D, VIGET N, BERNARD J, GUILLOT P, DUVIVIER C, BILLAUD E, RAFFI F. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. J Antimicrob Chemother 2012; 67: 2222-2230.
78. VESCINI F, COZZI-LEPRI A, BORDERI M, RE MC, MAGGIOLO F, DE LUCA A, CASSOLA G, VULLO V, CAROSI G, ANTINORI A, TOZZI V, MONFORTE AD, FOR THE ICONA FOUNDATION STUDY GROUP. Prevalence of hypovitaminosis d and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large italian Cohort. J Acquir Immune Defic Syndr 2011; 58: 163-172.
79. VAN DEN BOUT-VAN DEN BEUKEL CJ, FIEVEZ L, MICHELS M, SWEEP FC, HERMUS AR, BOSCH ME, BURGER DM, BRAVENBOER B, KOOPMANS PP, VAN DER VEN AJ. Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008; 24: 1375-1382.
80. STEPHENSEN CB, MARQUIS GS, KRUZICH LA, DOUGLAS SD, ALDROVANDI GM, WILSON CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006; 83: 1135-1141.
81. RODRÍGUEZ M, DANIELS B, GUNAWARDENE S, ROBBINS GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses 2009; 25: 9-14.
82. BANG UC, SHAKAR SA, HITZ MF, JESPERSEN MS, ANDERSEN O, NIELSEN SD, JENSEN JE. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: a descriptive cross-sectional study. Scand J Infect Dis 2010; 42: 306-310.
83. CRUTCHLEY RD, GATHE JC, MAYBERRY C, TRIEU A, ABUGHOSH S, GAREY KW. Risk factors for vitamin D deficiency in HIV-infected patients in the South Central United States. AIDS Res Hum Retroviruses 2012; 28: 454-459.
84. MUELLER NJ, FUX CA, LEDERGERBER B, ELZI L, SCHMID P, DANG T, MAGENTA L, CALMY A, VERGOPOULOS A, BISCHOFFFERRARI HA, SWISS HIV COHORT STUDY. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy naive and successfully treated Swiss HIV patients.AIDS 2010; 24: 1127-1134.
85. HAUG CJ, AUKRUST P, HAUG E, MORKRID L, MULLER F, FROLAND SS. Severe deficiency of 1,25-dihydroxyvitamin D3 in human immunodeficiency virus infection: Association with immunologic hyperactivity and only minor changes in calcium homeostasis. J Clin Endocrinol Metab 1998; 83: 3832-3838.
86. HOLICK MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062-2072.
87. WILLIS CM, LAING EM, HALL DB, HAUSMAN DB, LEWIS RD. A prospective analysis of plasma 25- hydroxyvitamin D concentrations in white and black prepubertal females in the southeastern United States. Am J Clin Nutr 2007; 85: 124-130.
88. WORTSMAN J, MATSUOKA LY, CHEN TC, LU Z, HOLICK MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000; 72: 690-693.
89. CONESA-BOTELLA A, FLORENCE E, LYNEN L, COLEBUNDERS R, MENTEN J, MORENO-REYES R. Decrease of vitamin D concentration in patients with HIV infection on a non nucleoside reverse transcriptase inhibitor-containing regimen. AIDS Res Ther 2010; 7: 1-6.
90. MEHTA S, MUGUSI FM, SPIEGELMAN D, VILLAMOR E, FINKELSTEIN JL, HERTZMARK E, GIOVANNUCCI EL, MSAMANGA GI, FAWZI WW. Vitamin D status and its association with morbidity including wasting and oppor tunistic illnesses in HIV-infected women in Tanzania. AIDS Patient Care STDS 2011; 25: 579-585.
91. ARPADI SM, MCMAHON D, ABRAMS EJ, BAMJI M, PURSWANI M, ENGELSON ES, HORLICK M, SHANE E. Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics 2009; 123: e121-126.
92. MEHTA S, GIOVANNUCCI E, MUGUSI FM, SPIEGELMAN D, ABOUD S, HERTZMARK E, MSAMANGA GI, HUNTER D, FAWZI WW. Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS One 2010; 5: e8770.
93. COZZOLINO M, VIDAL M, ARCIDIACONO MV, TEBAS P, YARASHESKI KE, DUSSO AS. HIV protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17: 513-520.
94. HARIPARSAD N, NALLANI SC, SANE RS, BUCKLEY DJ, BUCKLEY AR, DESAI PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and phenobarbital. J Clin Pharmacol 2004; 44: 1273-1281.
95. BROWN T, MC COMSEY G. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther 2010; 15: 425-429.
96. ELLFOLK M, NORLIN M, GYLLENSTEN K, WIKVALL K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75: 1392-1399.
97. PASQUET A, VIGET N, AJANA F, DE LA TRIBONNIERE X, DUBUS S, PACCOU J, LEGROUX-GÉROT I, MELLIEZ H, CORTET B, YAZDANPANAH Y. Vitamin D deficiency in HIV infected patients: associated with NNRTI or efavirenz use? AIDS 2011; 25: 873-874.
98. WELZ T, CHILDS K, POST FA. Do nevirapine and efavirenz affect vitamin D homeostasis similarly? AIDS 2011; 25: 875-876.
99. FUX CA, BAUMANN S, FURRER H, MUELLER NJ. Is lower serum 25-hydroxy vitamin D associated with efavirenz or the non-nucleoside reverse transcriptase inhibitor class? AIDS 2011; 25: 876-878.
100. LATTUADA E, LANZAFAME M, ZOPPINI G, CONCIA E, VENTO S. No influence of nevirapine on vitamin D deficiency in HIV-infected patients. AIDS Res Hum Retroviruses 2009; 25: 849-850.
101. WOHL D, DOROANA M, ORKI C, PILOTTO JH, SUNGKANUPARPH S, YENI P, VANVEGGEL S, DECKX H, BOVEN K. Change in vitamin D levels smaller, and risk of development of severe vitamin D deficiency lower, among HIV-1-infected, treatment-naive adults receiving TMC278 compared with efavirenz: 48-week results from the Phase III ECHO trial. Abstracts of the 17th Annual Conference of the British HIV Association (BHIVA), Bournemouth, UK, 2011.
102. FOX J, PETERS B, PRAKASH M, ARRIBAS J, HILL A, MOECKLINGHOFF C. Improvement in Vitamin D deficiency following antiretroviral regime change: results from the MONET trial. AIDS Res Hum Retroviruses 2010; 26: 1-6.
103. TORTI C, MAZZIOTTI G, SOLDINI PA, FOCÀ E, MAROLDI R, GOTTI D, CAROSI G, GIUSTINA A. High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine 2012; 41: 512-517.
104. LABARGA P, BARREIRO P, MARTIN-CARBONERO L, RODRIGUEZ- NOVOA S, SOLERA C, MEDRANO J, RIVAS P, ALBALATER M, BLANCO F, MORENO V, VISPO E, SORIANO V. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009; 23: 689-696.
105. MARTIN A, BLOCH M, AMIN J, BAKER D, COOPER DA, EMERY S, CARR A. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavirlamivudine: a randomized, 96-week trial. Clin Infect Dis 2009; 49: 1591-1601.
106. GALLANT JE, STASZEWSKI S, POZNIAK AL, DEJESUS E, SULEIMAN JM, MILLER MD, COAKLEY DF, LU B, TOOLE JJ, CHENG AK, 903 STUDY GROUP. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral naive patients: a 3- year randomized trial. JAMA 2004; 292: 191-201.
107. LABARGA P, BARREIRO P, MARTIN-CARBONERO L, ALVAREZ E, SOLERA C, PINILLA J. Prevalence and mechanisms of hyperparathyroidism in HIV+ patiens treated with TDF. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA, 2011.
108. ROSENVINGE MM, GEDELA K, COPAS AJ, WILKINSON A, SHEEHY CA, BANO G, HAY PE, PAKIANATHAN MR, SADIQ ST. Tenofovir-linked hyperparathyroidism is independently associated with the presence of vitamin D deficiency. J Acquir Immune Defic Syndr 2010; 54: 496-499.
109. CHILDS KE, FISHMAN SL, CONSTABLE C, GUTIERREZ JA, WYATT CM, DIETERICH DT, MULLEN MP, BRANCH AD. Short communication: inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. AIDS Res Hum Retroviruses 2010; 26: 855-899.
110. POCATERRA D, RICCI E, CARENZI L, SCHIAVINI M, MERAVIGLIA P, MINISCI D. Prevalence of hypovitaminosis D and factors associated in a sample of HIV patients. Abstracts from the 18th International AIDS Conference Vienna, Austria, 2010.
111. FERNANDEZ-RIVERA J, GARCIA R, LOZANO F, MACÍAS J, GARCÍA-GARCÍA JA, MIRA JA, CORZO JE, GÓMEZ-MATEOS J, RUEDA A, SÁNCHEZ-BURSON J, PINEDA JA. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4: 337-346.
112. DUVIVIER C, KOLTA S, ASSOUMOU L, GHOSN J, ROZENBERG S, MURPHY RL, KATLAMA C, COSTAGLIOLA D, ANRS 121 HIPPOCAMPE STUDY GROUP. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23: 817-824.
113. MADEDDU G, SPANU A, SOLINAS P, CALIA GM, LOVIGU C, CHESSA F, MANNAZZU M, FALCHI A, MURA MS, MADEDDU G. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48: 39-48.
114. FOCÀ E, MOTTA D, BORDERI M, GOTTI D, ALBINI L, CALABRESI A, IZZO I, BELLAGAMBA R, NARCISO P, SIGHINOLFI L, CLÒ A, GIBELLINI D, QUIROS-ROLDAN E, BRIANESE N, CESANA BM, RE MC, TORTI C. Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infect Dis 2012; 12: 38.
115. TEBAS P, UMBLEJA T, DUBÉ M. Initiation of ART is associated with bone loss independent of the specific ART regimen. The results of ACTG A5005s Proceedings of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007.
116. GRUND B, PENG G, GIBERT CL, HOY JF, ISAKSSON RL, SHLAY JC, MARTINEZ E, REISS P, VISNEGARWALA F, CARR AD, INSIGHT SMART BODY COMPOSITION SUBSTUDY GROUP. Continuous antiretroviral therapy (ART) decreases bone mineral density. AIDS 2009; 23: 1519-1529.
117. MONDY K, POWDERLY WG, CLAXTON SA, YARASHESKI KH, ROYAL M, STONEMAN JS, HOFFMANN ME, TEBAS P. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38: 426-431.
118. MCCOMSEY GA, KENDALL MA, TEBAS P, SWINDELLS S, HOGG E, ALSTON-SMITH B, SUCKOW C, GOPALAKRISHNAN G, BENSON C, WOHL DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21: 2473-2482.
119. GUARALDI G, ORLANDO G, MADEDDU G, VESCINI F, VENTURA P, CAMPOSTRINI S, MURA MS, PARISE N, CAUDARELLA R, ESPOSITO R. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis. HIV Clin Trials 2004; 5: 269-277.
120. TRIANT VA, LEE H, HADIGAN C, GRINSPOON SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrinol Metab 2007; 92: 2506-2512.
121. CURRIER JS, TAYLOR A, BOYD F, DEZII CM, KAWABATA H, BURTCEL B, MAA JF, HODDER S. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33: 506-512.
122. GRINSPOON SK, GRUNFELD C, KOTLER DP, CURRIER JS, LUNDGREN JD, DUBÉ MP, LIPSHULTZ SE, HSUE PY, SQUIRES K, SCHAMBELAN M, WILSON PW, YARASHESKI KE, HADIGAN CM, STEIN JH, ECKEL RH. State of the Science Conference Initiative to Decrease Cardiovascular Risk and Increase Quality of Care for Patients Living With HIV/AIDS. Circulation 2008; 118: 198-210.
123. DAD STUDY GROUP, FRIIS-MØLLER N, REISS P, SABIN CA, WEBER R, MONFORTE AD, EL-SADR W, THIÉBAUT R, DE WIT S, KIRK O, FONTAS E, LAW MG, PHILLIPS A, LUNDGREN JD. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356: 1723-1735.
124. GRUNFELD C, DELANEY JA, WANKE C, CURRIER JS, SCHERZER R, BIGGS ML, TIEN PC, SHLIPAK MG, SIDNEY S, POLAK JF, O'LEARY D, BACCHETTI P, KRONMAL RA. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009; 23: 1841-1849.
125. HSUE PY, HUNT PW, SCHNELL A, KALAPUS SC, HOH R, GANZ P, MARTIN JN, DEEKS SG. Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 2009; 23: 1059-1067.
126. CROWE SM, WESTHORPE C, MUKHAMEDOVA N, JAWOROWSKI A, SVIRIDOV D, BUKRINSKY M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 2010; 87: 589-598.
127. CHOI AI, LO JC, MULLIGAN K, SCHNELL A, KALAPUS SC, LI Y, HUNT PW, MARTIN JN, DEEKS SG, HSUE PY. Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis 2011; 52: 941-944.
128. ROSS A, JUDD SE, KUMARI M, HILEMAN C, STORER N, LABBATO D, TANGPRICHA V, MCCOMSEY GA. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-infected individuals. Antivir Ther 2011; 16: 555-563.
129. SHIKUMA CM, SETO T, LIANG CY, BENNETT K, DEGRUTTOLA V, GERSCHENSON M, STEIN JH, BUDOFF M, HODIS HN, DELANEY JA, OGATA-ARAKAKI D, PRAMYOTHIN P, CHOW D. Vitamin D levels and markers of arterial dysfunction in HIV. AIDS Res Hum Retroviruses 2012; 28: 793-797.
130. LAI H, GERSTENBLITH G, FISHMAN EK, BRINKE J, KICKLER T, TONG W, BHATIA S, HONG T, CHEN S, LI J, DETRICK B, LAI S. Vitamin D deficiency is associated with silent coronary artery disease in cardiovascularly asymptomatic African Americans with HIV infection. Clin Infect Dis 2012; 54: 1747-1755.
131. TEBAS P. Insulin resistance and diabetes mellitus associated with antiretroviral use in HIV-infected patients: pathogenesis, prevention, and treatment options. J Acquir Immune Defic Syndr 2008; 49(S2): S86-S92.
132. BROWN TT, COLE SR, LI X, KINGSLEY LA, PALELLA FJ, RIDDLER SA, VISSCHER BR, MARGOLICK JB, DOBS AS. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005; 165: 1179-1184.
133. MITRI J, MURARU MD, AG PITTAS. Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr 2011; 65: 1005-1015.
134. SZEP Z, GUARALDI G, SHAH SS, LO RE V 3RD, RATCLIFFE SJ, ORLANDO G, CARLI F, ROSSI R, ROCHIRA V, TEBAS P. Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS 2011; 25: 525-529.
135. MAESTRO B, CAMPION J, DAVILA N, CALLE C. Stimulation by 1,25-dihydroxyvitamin D3 of insulin receptor expression and insulin responsiveness for glucose transport in U-937 human promonocytic cells. Endocr J 2000; 47: 383-391.
136. NORMAN AW, FRANKEL JB, HELDT AM, GRODSKY GM. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209(4458): 823-825.
137. CHERTOW BS, SIVITZ WI, BARANETSKY NG, CLARK SA, WAITE A, DELUCA HF. Cellular mechanisms of insulin release: the effects of vitamin D deficiency and repletion on rat insulin secretion. Endocrinology 1983; 113: 1511-1518.
138. PITTAS AG, HARRIS SS, STARK PC, DAWSON-HUGHES B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care 2007; 30: 980-986.
139. VAN DEN BOUT-VAN DEN BEUKEL CJ, VAN DEN BOS M, OYEN WJ, HERMUS AR, SWEEP FC, TACK CJ, BOSCH ME, BURGER DM, KOOPMANS PP, VAN DER VEN AJ. The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D deficient HIV-1-infected patients. HIV Med 2008; 9: 771-779.
140. HIDA Y, KAWADA T, KAYAHASHI S, ISHIHARA T, FUSHIKI T. Counteraction of retinoic acid and 1,25-dihydroxyvitamin D3 on up-regulation of adipocyte differentiation with PPARgamma ligand, an antidiabetic thiazolidinedione, in 3T3-L1 cells. Life Sci 1998; 62: L205-211.
141. BLUMBERG JM, TZAMELI I, ASTAPOVA I, LAM FS, FLIER JS, HOLLENBERG AN. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3-L1 cells. J Biol Chem 2006; 281: 11205-11213.
142. KONG J, LI YC. Molecular mechanism of 1,25-dihydroxyvitamin D3 inhibition of adipogenesis in 3T3-L1 cells. Am J Physiol Endocrinol Metab 2006; 290: E916-924.
143. EVANS RM, BARISH GD, WANG YX. PPARs and the complex journey to obesity. Nat Med 2004; 10: 355-361.
144. ANSEMANT T, MAHY S, PIROTH C, ORNETTI P, EWING S, GUILLAND JC, CROISIER D, DUVILLARD L, CHAVANET P, MAILLEFERT JF, PIROTH L. Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients. BMC Infectious Diseases 2013; 13: 7.
145. POUDEL-TANDUKAR K, POUDEL KC, JIMBA M, KOBAYASHI J, JOHNSON CA, PALMER PH. Serum 25-hydroxyvitamin D levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res Hum Retroviruses [Epub ahead of print]
146. EUROPEAN AIDS CLINICAL SOCIETY. Guidelines: prevention and management of non-infectious comorbidities in HIV. Available at http://www. europeanaidsclinicalsociety.org/images/stories/EACS-Pdf/EacsGuidelines-v6. 1-2edition.pdf. Accessed January 2013.
147. HEANEY RP, DAVIES KM, CHEN TC, HOLICK MF, BARGERLUX MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 2003; 77: 204-210.
148. HAVENS PL, MULLIGAN K, HAZRA R, FLYNN P, RUTLEDGE B, VAN LOAN MD, LUJAN-ZILBERMANN J, KAPOGIANNIS BG, WILSON CM, STEPHENSEN CB, AND THE ADOLESCENT MEDICINE TRIALS NETWORK FOR HIV/AIDS INTERVENTIONS (ATN) 063 STUDY TEAM. Serum 25-Hydroxyvitamin D response to vitamin D3 supplementation 50,000 IU monthly in youth with HIV-1 infection. J Clin Endocrinol Metab 2012; 97: 4004-4013.
149. CHILDS K, FISHMAN S, FACTOR S, DIETERICH D, MULLEN M, BRANCH A. First report of dose/response data of HIV-infected men treated with vitamin D3 Supplement. 17th Conference on Retroviruses and Opportunistic Infections San Francisco, California, 2010.
150. HAVENS P, HAZRA R, STEPHENSEN C, VAN LOAN M, RUTLEDGE B, BETHEL J, PAN C, LIU N, LUJAN-ZILBERMANN J, MULLIGAN K, AND ATN 063 STUDY TEAM. Vitamin D3 supplementation decreases PTH in HIV-infected youth being treated with TDF-containing combination ART: a randomized, double-blind, placebo-controlled multicenter trial: Adolescent Trials Network Study 063. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA, 2011.
151. BUCCISANO F, ROSSI FM, VENDITTI A, DEL POETA G, COX MC, ABBRUZZESE E, RUPOLO M, BERRETTA M, DEGAN M, RUSSO S, TAMBURINI A, MAURILLO L, DEL PRINCIPE MI, POSTORINO M, AMADORI S, GATTEI V. CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias. Br J Haematol 2004; 125: 203-212.
152. LONGENECKER C, HILEMAN C, CARMAN C, ROSS AA, SEYDAFKAN S, BROWN TT, LABBATO DE, STORER N, TANGPRICHA V, MCCOMSEY GA. Vitamin D supplementation and endothelial function among vitamin D-deficient HIV-infected persons: a randomized placebo-controlled trial. Abstracts from the 18th Conference on Retroviruses and Opportunistic Infections Boston, MA, 2011.